AmMax
AmMax Bio is a clinical-stage biopharmaceutical company founded in 2020 that develops antibody-drug conjugates and monoclonal antibodies for oncology, with lead programs AMB-104 (acute myeloid leukemia) and AMB-066 (colorectal cancer minimal residual disease) targeting patients with high unmet need.
- Company typePrivate
- Founded2020
- HeadquartersRedwood City, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What AmMax does
AmMax Bio is a clinical-stage biopharmaceutical company founded in 2020 by Larry Hsu, PhD in partnership with Amgen and headquartered in Redwood City, California. The company develops antibody-drug conjugates (ADCs) and monoclonal antibodies for oncology applications, constructing both monospecific and bispecific ADCs from clinically validated antibody, linker, and payload components. Its pipeline includes AMB-104, a first-in-class ADC for acute myeloid leukemia (AML) targeting venetoclax/azacitidine-resistant monocytic AML cells and currently in IND-enabling studies; AMB-066, a CSF1R-targeting monoclonal antibody in Phase 2a for colorectal cancer minimal residual disease (CRC MRD); AMB-051, an intra-articular injection for tenosynovial giant cell tumor (TGCT); and bispecific ADC programs AMB-113 and AMB-118 targeting castrate-resistant prostate cancer and various solid tumors, respectively.
AmMax operates a partnership-driven model: it licenses core ADC technologies (e.g., Lonza's GlycoConnect, HydraSpace, and SYNtecan linker-payload platforms) and secures exclusive rights to discovery-stage assets (e.g., the worldwide exclusive license from MD Anderson for AMB-066). Revenue mechanics consist of upfront and milestone payments from these licensing partners today, with planned future income from commercialization of the pipeline. The company does not currently commercialize any product and has no reported revenue. GTM execution relies on academic medical center partnerships for clinical trial conduct — most notably MD Anderson for AMB-066 Phase 2a — together with industry-conference presence (BIO-Europe Spring, Oppenheimer Healthcare Private Company Showcase) for investor and partner outreach.
The customer base is unusually structured for a biotech: rather than commercial payers or prescribing physicians, the immediate counterparties are research and licensing partners (Lonza, MD Anderson, Amgen) and, by extension, the oncology patient populations targeted across the four lead programs (AML, CRC MRD, CRPC, and solid tumors, collectively addressing >$14 billion in cited addressable markets). The company's competitive positioning emphasizes reduced development risk through use of validated components, large addressable markets in indications with limited or no approved therapies, and a leadership team with prior commercial-scale drug launches and billion-dollar biopharma company-building experience.
AmMax firmographics
Firmographics- Name
- AmMax
- Legal name
- AmMax Bio, Inc.
- Website
- https://ammaxbio.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- AmMax Bio is a clinical-stage biopharmaceutical company founded in 2020 that develops antibody-drug conjugates and monoclonal antibodies for oncology, with lead programs AMB-104 (acute myeloid leukemia) and AMB-066 (colorectal cancer minimal residual disease) targeting patients with high unmet need.
- Ownership category
- akta.pro rank
AmMax industry classification
Industry- Product category
- Oncology Biopharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)
- akta.pro secondary industries
- Bispecific & Multispecific Antibodies (HLAAAAAF), Oncology Specialty Pharmaceuticals (HLAIACAA), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
Keywords
Where AmMax is headquartered
LocationHeadquarters
- HQ city
- Redwood City
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
AmMax business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Future Drug Commercialization: As a clinical-stage biopharmaceutical company, AmMax Bio currently has no revenue. The company's future revenue model will be derived from the commercialization of its ADC pipeline, including AMB-104 for AML and AMB-066 for CRC MRD, as well as potential bispecific ADC programs for solid tumors and castrate-resistant prostate cancer.
- Licensing and Milestone Payments: AmMax Bio receives upfront, milestone, and potential royalty payments through licensing agreements with strategic partners such as Lonza for ADC technologies, while maintaining responsibility for research, development, manufacturing, and commercialization of resulting ADC products.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
AmMax product offering
Product offeringCore offering
AmMax Bio is a clinical-stage biopharmaceutical company developing a portfolio of antibody-drug conjugates (ADCs) and monoclonal antibodies for oncology. Its lead programs include AMB-104, a first-in-class ADC for acute myeloid leukemia (AML) targeting venetoclax/azacitidine-resistant monocytic cells, and AMB-066, a CSF1R-targeting monoclonal antibody currently in Phase 2a for colorectal cancer minimal residual disease (CRC MRD). The company also pursues AMB-051 for tenosynovial giant cell tumor (TGCT) and bispecific ADCs for solid tumors including castrate-resistant prostate cancer.
Product overview
AmMax Bio is a clinical-stage biotechnology company developing a portfolio of antibody-drug conjugates (ADCs) and monoclonal antibodies for oncology. The core product portfolio includes: AMB-104, a first-in-class ADC for acute myeloid leukemia (AML); AMB-066, a monoclonal antibody in Phase 2a for colorectal cancer minimal residual disease (CRC MRD); AMB-051, an intra-articular injection for tenosynovial giant cell tumor; and bispecific ADCs for solid tumors including castrate-resistant prostate cancer. The company leverages clinically validated components to reduce development risk and accelerate clinical timelines.
Differentiator
Problem solved
Functional benefit
Products and services
- AMB-104 First-in-class antibody-drug conjugate targeting acute myeloid leukemia (AML), leveraging a clinically validated monoclonal antibody to deliver a cytotoxic payload to AML cells, including those resistant to venetoclax/azacitidine treatments. Currently in IND-enabling studies.
- AMB-066
Companies that use AmMax
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles3 records
AmMax technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
AmMax partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and flagship.
- LonzacoreNon-exclusive licensing agreement providing AmMax access to Lonza's GlycoConnect, HydraSpace, and SYNtecan linker-payload technologies for development of antibody-drug conjugates targeting hematological cancers. AmMax engineered AMB-104 combining these technologies with its monoclonal antibody. Lonza provides manufacturing of licensed technology components and is eligible for upfront, milestone, and royalty payments on net sales.
- MD Anderson Cancer CentercoreWorldwide exclusive license agreement and clinical trial agreement to develop AmMax's AMB-066 monoclonal antibody therapy as first-in-class treatment for colorectal cancer with minimal residual disease (CRC MRD) and other solid tumors. The collaboration builds on preclinical discoveries by MD Anderson researchers led by Dr. Scott Kopetz. Patient enrollment in Phase 2a proof-of-concept study is being conducted at MD Anderson.
- AmgenflagshipAmMax Bio was founded in 2020 by Larry Hsu, PhD in partnership with Amgen, establishing the company's foundational relationship for ADC platform development and oncology therapeutics research.
Scale indicators7 records
Recent moves6 records
Expansion highlights5 records
AmMax competitors and assessment
Company assessmentEmerging players
- Macrogenics: Clinical-stage oncology company with bispecific antibody and ADC programs in hematologic and solid tumor indications. Comparable on bispecific antibody engineering focus and oncology pipeline breadth.
- Tubulis: Earlier-stage ADC company developing novel linker chemistries and payload platforms for oncology. Comparable on proprietary payload technology approach but at earlier stage than AmMax.
Direct peers
- CytomX Therapeutics: Clinical-stage oncology company using a proprietary Probody platform to develop conditionally activated ADCs and immunotherapies. Comparable platform-based ADC approach with multiple partnered programs.
- Mersana Therapeutics: Clinical-stage ADC developer building both monospecific and bispecific ADCs for oncology, including hematologic and solid tumor programs. Most directly comparable to AmMax on ADC platform technology, stage, and pipeline breadth.
- Heidelberg Pharma: Clinical-stage ADC developer using proprietary amanitin-based payload technology. Comparable clinical-stage ADC company with proprietary payload differentiation similar to AmMax's Lonza-licensed payload platform.
- ProfoundBio: Clinical-stage ADC company with a proprietary linker-payload platform and both monospecific and bispecific ADCs in oncology. Closely comparable to AmMax on technology architecture, target selection, and stage of development.
- Bolt Biotherapeutics: Clinical-stage developer of bispecific immune-stimulating ADCs (ISACs) for oncology. Comparable to AmMax's bispecific ADC pipeline strategy and clinical-stage positioning.
- Pyxis Oncology: Clinical-stage oncology company developing ADCs and immunotherapies, with programs in hematologic malignancies and solid tumors. Directly comparable on ADC pipeline focus and clinical-stage scale.
Broad incumbents
- ImmunoGen (AbbVie): Pioneer in ADC technology and developer of Elahere; now part of AbbVie. Represents the established incumbent whose ADC platform and pipeline define the category AmMax competes within.
- Daiichi Sankyo: Global pharmaceutical leader in ADCs with Enhertu and Datroway (with AstraZeneca). The dominant commercial ADC player whose target selection, payload chemistry, and clinical scale define competitive benchmarks for ADC developers like AmMax.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
AmMax social profiles
Digital presenceAmMax financial estimates
Financial estimateRevenue estimate
Valuation estimate
AmMax leadership team
Management profileNumber of profiles
Profiles12 records
AmMax funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AmMax M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AmMax
What does AmMax do?
AmMax Bio is a clinical-stage biopharmaceutical company developing a portfolio of antibody-drug conjugates (ADCs) and monoclonal antibodies for oncology. Its lead programs include AMB-104, a first-in-class ADC for acute myeloid leukemia (AML) targeting venetoclax/azacitidine-resistant monocytic cells, and AMB-066, a CSF1R-targeting monoclonal antibody currently in Phase 2a for colorectal cancer minimal residual disease (CRC MRD). The company also pursues AMB-051 for tenosynovial giant cell tumor (TGCT) and bispecific ADCs for solid tumors including castrate-resistant prostate cancer.
Is AmMax a public or private company?
AmMax is a private company. It is classified as venture growth investor backed and is currently operating.
When was AmMax founded?
AmMax was founded in 2020. It employs 11 to 50 people.
Where is AmMax based?
AmMax is headquartered in Redwood City, United States, in the North America region.
How does AmMax make money?
Two revenue lines are on record. Future Drug Commercialization is the primary driver. The others are licensing and Milestone Payments.
Who are AmMax's main competitors?
Emerging players on record are Macrogenics and Tubulis. Direct peers are CytomX Therapeutics, Mersana Therapeutics, Heidelberg Pharma, ProfoundBio, Bolt Biotherapeutics and Pyxis Oncology. Broad incumbents are ImmunoGen (AbbVie) and Daiichi Sankyo.
Does AmMax have an API?
No public API is recorded for AmMax.
What industry is AmMax in?
AmMax's product category is Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates, with a secondary code of HLAAAAAF, Bispecific & Multispecific Antibodies. Its NAICS code is 325412 and its SIC code is 2834.